A Study of Immune-adjuvant Effect of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Hypogammaglobulinemia and Impaired Response to Vaccinations - RV-CL-CLL-PI-002544
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2018
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; Influenza virus vaccine; Pneumococcal vaccine
- Indications Agammaglobulinaemia; Chronic lymphocytic leukaemia; Influenza virus infections; Pneumonia
- Focus Pharmacodynamics
- 22 Feb 2017 Status changed from active, no longer recruiting to discontinued due to slow accrual.
- 07 Oct 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
- 07 Oct 2016 Status changed from recruiting to active, no longer recruiting.